Crysvita sales push Ultragenyx ahead for the quarter

Sales of Ultragenyx's Crysvita hint at the XLH therapy's launch trajectory as it drove the biotech's revenues for the quarter.

Ultragenyx and partner Kyowa Hakko Kirin Co. Ltd. received FDA approval on April 17, 2018 for Crysvita burosumab-twza to treat X-linked hypophosphatemia (XLH) in patients aged one year and older, the first approval in the U.S. for the indication.